Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cures 2.0: Can Congress Recapture The Legislative Magic?

Executive Summary

Primary sponsors of the 21st Century Cures Act are trying to get the band back together. Is there hope to recapture a bipartisan, pro-innovation spirit in the current US Congress?

You may also be interested in...



Real-World Evidence, Digital Health, Insurance Coverage Reforms On Cures 2.0 Agenda

All three areas need work following enactment of the original 21st Century Cures Act, authors Fred Upton and Diana DeGette write in vision statement.

Gene Therapy Payment Models Could Be One Focus For 'Cures II'

House Republicans are eager to keep working on legislation to permit innovative payment models for curative gene and cell therapies. Democrats, for now, are focused on other priorities.

The Real Impact Of ‘Cures’: The Hype Means Something

It is hard to find anything in the 21st Century Cures Act that justifies the hyperbole around its signing – or the criticism that it undermines patient safety. But, for the biopharma industry, the hype is important as a sign that pro-innovation messages have bipartisan appeal.

Related Content

Topics

UsernamePublicRestriction

Register

PS140669

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel